Absenteeism and productivity among employees being treated for hepatitis CRichard A Brook
Retrospective Analysis, The JeSTARx Group, Newfoundland, NJ 07435 1710, USA
Am J Manag Care 17:657-64. 2011
..To compare productivity, absence days, and absence costs for treated (HCV-Tx) and untreated (HCV-NoTx) US employees with hepatitis C virus (HCV) infection...
Absenteeism and health-benefit costs among employees with MSRichard A Brook
Retrospective Research, The JeSTARx Group, Newfoundland, NJ 07435 1710, USA
Curr Med Res Opin 25:1469-76. 2009
..The purpose of this analysis was to assess the differences in lost time and health-benefit costs (HBCs) among employees treated with disease modifying treatments (DMTs) for multiple sclerosis (MS)...
- Functional dyspepsia impacts absenteeism and direct and indirect costs
Richard A Brook
Retrospective Analysis, The JeSTARx Group, Newfoundland, New Jersey 07435 1710, USA
Clin Gastroenterol Hepatol 8:498-503. 2010
..Few data on absenteeism and no objective information are available. This study aimed to assess the impact of FD on costs and effects on absenteeism and work output (productivity)...
- Cost of gastro-oesophageal reflux disease to the employer: a perspective from the United States
R A Brook
The JeSTARx Group, Newfoundland, NJ 07435 1710, USA
Aliment Pharmacol Ther 26:889-98. 2007
..Employers pay more than just salary for their employees. Previous studies have largely focused on direct medical and prescription drug costs of gastro-oesophageal reflux disease (GERD), and few have reported on total absenteeism costs...
- Chronic gout: epidemiology, disease progression, treatment and disease burden
Richard A Brook
The JeSTARx Group, Newfoundland, NJ, USA
Curr Med Res Opin 26:2813-21. 2010
..Diagnosed gout cases have been estimated at 2.13% of the 2009 US population. The highest incidence occurs in the 65+ year age group, with males more than twice as likely to be afflicted as females...
- Employee costs before and after treatment initiation for bipolar disorder
Richard A Brook
Retrospective Analysis, The JeSTARx Group, Newfoundland, NJ 07435 1710, USA
Am J Manag Care 13:179-86. 2007
..To examine pretreatment and posttreatment total medical costs and overall mental healthcare costs for patients with bipolar disorder (BPD) treated with different medication regimens (alone and in combination) vs an untreated (UnTx) cohort...
- Excess comorbidity prevalence and cost associated with functional dyspepsia in an employed population
Richard A Brook
The JeSTARx Group, 18 Hirth Drive, Newfoundland, NJ 07435 1710, USA
Dig Dis Sci 57:109-18. 2012
..Limited published data exist on the associated comorbid conditions with functional dyspepsia (FD)...
- Absenteeism and productivity among employees being treated for hepatitis c
Richard A Brook
Retrospective Analysis, The JeSTARx Group, 18 Hirth Dr, Newfoundland, NJ 07435 1710 E mail
Am J Manag Care 17:657-64. 2011
..New treatments are needed with improved adverse effect profiles that result in reduced absence from work and improved productivity among HCV-infected persons...
- The economic burden of gout on an employed population
Richard A Brook
The JeSTARx Group, Newfoundland, NJ 07435 1710, USA
Curr Med Res Opin 22:1381-9. 2006
....
- Annual incremental health benefit costs and absenteeism among employees with and without rheumatoid arthritis
Nathan L Kleinman
Data Analytics, HCMS Group, Cheyenne, WY, USA
J Occup Environ Med 55:240-4. 2013
..To assess the impact of rheumatoid arthritis (RA) on absence time, absence payments, and other health benefit costs from the perspective of US employers...
- Lost time, absence costs, and reduced productivity output for employees with bipolar disorder
Nathan L Kleinman
HCMS Group, Cheyenne, Wyoming 82001, USA
J Occup Environ Med 47:1117-24. 2005
..We sought to evaluate the incremental health-related lost work time and at-work productivity loss for employees with bipolar disorder (BPD)...
- The economic impact of bipolar disorder in an employed population from an employer perspective
Harold H Gardner
Human Capital Management Services, Cheyenne, WY 82001, USA
J Clin Psychiatry 67:1209-18. 2006
..4 days annually (p < .05). CONCLUSION: The impact of bipolar disorder can be costly in the workplace, leading to increased health benefit costs and increased absenteeism...
- Costs of physical and mental comorbidities among employees: a comparison of those with and without bipolar disorder
Krithika Rajagopalan
Health Economics Outcomes Research, AstraZeneca Pharmaceuticals, Wilmington, DE 19850 5437, USA
Curr Med Res Opin 22:443-52. 2006
..To compare the cost and utilization of health care services for various comorbid conditions among employees with bipolar disorder (BPD) and two other population cohorts: employees without BPD and employees with other mental disorders (OMD)...
- Objective measurement of work absence and on-the-job productivity: a case-control study of US employees with and without gastroesophageal reflux disease
Peter Wahlqvist
AstraZeneca R and D Molndal, Molndal, Sweden
J Occup Environ Med 50:25-31. 2008
..To establish an association between gastroesophageal reflux disease (GERD) and increased work absence, as well as reduced productivity while at work, by using objective productivity measurements...
- The impact of gout on work absence and productivity
Nathan L Kleinman
HCMS Group, Cheyenne, WY 82001, USA
Value Health 10:231-7. 2007
..The goal of this analysis was to evaluate the impact of gout, a painful inflammatory arthritis condition, on an employed population's health-related work absence and objectively measured productivity output...
- Metabolic syndrome-related conditions among people with and without gout: prevalence and resource use
Suzanne Novak
Pharmacy Practice, University of Texas at Austin, Austin, TX, USA
Curr Med Res Opin 23:623-30. 2007
....
- Exploratory economic evaluation of patients with COPD on a combination product versus individual components (ipratropium bromide and albuterol)
John M York
Akita Biomedical Consulting, San Clemente, California 92672, USA
Adv Ther 24:757-71. 2007
..Future analyses should include clinical data to better elucidate the full impact of DN on healthcare resources and compliance in the COPD population...
